{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:19:07Z","timestamp":1783523947536,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Various molecular-targeted therapeutic agents that inhibit cytokines and immune checkpoints are used in clinical practice. Some of these biologics that control immunity, such as anti-interleukin-17, anti-programmed cell death protein-1, and anti-cytotoxic T-lymphocyte-associated protein antibodies, affect intestinal immune homeostasis and cause intestinal inflammation. Development of enteritis due to dupilumab (an anti-IL-4Ralpha monoclonal antibody) therapy is not yet reported in the literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 17-year-old man was administered an injection of dupilumab and continued to receive it for refractory atopic dermatitis. After 3\u00a0months of initiating dupilumab therapy, he developed intermittent abdominal pain, tenesmus, and had diarrhea. Colonoscopy examination showed decreased vascularity, mild friability, and erythema in the cecum, part of the ascending colon, sigmoid colon, and rectum without any pathogenic bacteria. Histological examination revealed moderate mixed inflammatory cell infiltration, cryptitis, destruction of the crypt, decreased goblet cells, mucosal erosions, and edema. He was diagnosed with UC and was prescribed oral mesalazine (4800\u00a0mg\/day) treatment. Within a month of the treatment, his diarrhea improved and the frequency of defecation decreased.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is a first report that dupilumab mimicked ulcerative colitis. Careful monitoring for adverse effects with the onset of an intestinal inflammation will be recommended after dupilumab administration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01803-8","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:03:07Z","timestamp":1620464587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0314-9196","authenticated-orcid":false,"given":"Yosuke","family":"Shimodaira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"issue":"8","key":"1803_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ncponc0558","volume":"3","author":"IB Weinstein","year":"2006","unstructured":"Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction\u2013a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006;3(8):448\u201357.","journal-title":"Nat Clin Pract Oncol"},{"issue":"2","key":"1803_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.2287","volume":"214","author":"JR Bradley","year":"2008","unstructured":"Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149\u201360.","journal-title":"J Pathol"},{"issue":"15","key":"1803_CR3","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2006","unstructured":"Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1803_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1159\/000493922","volume":"12","author":"J Philipose","year":"2018","unstructured":"Philipose J, Ahmed M, Idiculla PS, Mulrooney SM, Gumaste VV. Severe de novo ulcerative colitis following ixekizumab therapy. Case Rep Gastroenterol. 2018;12(3):617\u201321.","journal-title":"Case Rep Gastroenterol"},{"issue":"1","key":"1803_CR5","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1186\/s12885-019-6138-7","volume":"19","author":"K Yoshino","year":"2019","unstructured":"Yoshino K, Nakayama T, Ito A, Sato E, Kitano S. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. BMC Cancer. 2019;19(1):1019.","journal-title":"BMC Cancer"},{"issue":"2","key":"1803_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","volume":"129","author":"F Heller","year":"2005","unstructured":"Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, B\u00fcrgel N, Fromm M, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129(2):550\u201364.","journal-title":"Gastroenterology"},{"issue":"2","key":"1803_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/gutjnl-2014-308004","volume":"64","author":"S Danese","year":"2015","unstructured":"Danese S, Rudzi\u0144ski J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut. 2015;64(2):243\u20139.","journal-title":"Gut"},{"issue":"6","key":"1803_CR8","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1136\/gutjnl-2014-308337","volume":"64","author":"W Reinisch","year":"2015","unstructured":"Reinisch W, Pan\u00e9s J, Khurana S, Toth G, Hua F, Comer GM, Hinz M, Page K, O\u2019Toole M, Moorehead TM, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015;64(6):894\u2013900.","journal-title":"Gut"},{"issue":"13","key":"1803_CR9","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314.","journal-title":"N Engl J Med"},{"issue":"8","key":"1803_CR10","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1097\/MIB.0000000000000811","volume":"22","author":"J Li","year":"2016","unstructured":"Li J, Ueno A, Fort Gasia M, Luider J, Wang T, Hirota C, Jijon HB, Deane M, Tom M, Chan R, et al. Profiles of Lamina Propria T helper cell subsets discriminate between ulcerative colitis and Crohn\u2019s disease. Inflamm Bowel Dis. 2016;22(8):1779\u201392.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"1803_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139.","journal-title":"N Engl J Med"},{"key":"1803_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fcimb.2018.00395","volume":"8","author":"JC Hoving","year":"2018","unstructured":"Hoving JC. Targeting IL-13 as a host-directed therapy against ulcerative colitis. Front Cell Infect Microbiol. 2018;8:395.","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"1803_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/apt.15126","volume":"49","author":"B Verstockt","year":"2019","unstructured":"Verstockt B, Verstockt S, Creyns B, Tops S, Van Assche G, Gils A, Ceuppens JL, Vermeire S, Ferrante M, Breynaert C. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn\u2019s disease. Aliment Pharmacol Ther. 2019;49(5):572\u201381.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1803_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, Su\u00e1rez-Fari\u00f1as M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155\u201372.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1803_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/j.0022-202X.2004.23462.x","volume":"123","author":"Y Niwa","year":"2004","unstructured":"Niwa Y, Sumi H, Akamatsu H. An association between ulcerative colitis and atopic dermatitis, diseases of impaired superficial barriers. J Investig Dermatol. 2004;123(5):999\u20131000.","journal-title":"J Investig Dermatol"},{"key":"1803_CR16","unstructured":"Pharmaceuticals and Medical Devices Agency (Japanese). https:\/\/www.info.pmda.go.jp\/fsearchnew\/jsp\/menu_fukusayou_base.jsp. Search with the word of dupilumab and ulcerative colitis in Japanese. Accessed 15 Jan 2021."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01803-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01803-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01803-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:04:42Z","timestamp":1620464682000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01803-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1803"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01803-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"12 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics Committee of Akita University Graduate School of Medicine (Approved Number: 2621).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The written consent to publish the personal and clinical details (including figures) of the participant was obtained from the patient and his parent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}